Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

10.89 +0.05 (+0.46%)
Official Closing Price Updated: 4:15 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
1 Oversold Stock Primed to Rebound and 2 to Ignore
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned... 
Via StockStory
Topics ETFs Stocks World Trade
3 Small-Cap Stocks with Open Questions
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
Earnings Scheduled For April 30, 2025
 
Via Benzinga
Why Tandem Diabetes (TNDM) Shares Are Sliding Today
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 3.5% in the morning session after a Citi analyst downgraded the stock. Citi analyst Joanna Wuensch downgraded Tandem... 
Via StockStory
Topics Artificial Intelligence
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025
From Tandem Diabetes Care, Inc.
Via Business Wire
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process. 
Via Investor's Business Daily
1 Stock Under $50 with Solid Fundamentals and 2 to Ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
1 Growth Stock with All-Star Potential and 2 to Keep Off Your Radar
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin... 
Via Stocktwits
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Tandem Diabetes (NASDAQ:TNDM) and its peers. 
Via StockStory
Where Tandem Diabetes Care Stands With Analysts
 
Via Benzinga
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that... 
Via StockStory
Topics Bonds Stocks
1 Momentum Stock with Impressive Fundamentals and 2 to Turn Down
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) announced better-than-expected revenue in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full... 
Via StockStory
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Tandem Diabetes Care Announces Upcoming Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
 
Via Benzinga
Tandem Diabetes’s (NASDAQ:TNDM) Q1: Beats On Revenue, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full... 
Via StockStory
Tandem Diabetes (NASDAQ:TNDM) Posts Better-Than-Expected Sales In Q1, Stock Soars
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects... 
Via StockStory
Tandem Diabetes Care Announces First Quarter 2025 Financial Results
From Tandem Diabetes Care, Inc.
Via Business Wire
Insights into Tandem Diabetes Care's Upcoming Earnings
 
Via Benzinga
Tandem Diabetes (TNDM) Q1 Earnings Report Preview: What To Look For
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
1 Volatile Stock Worth Your Attention and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.